Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) were trading largely flat post-market Monday after the biotech company released its Q4 earnings report and issued 2025 guidance that was largely in line with Street expectations.

For Q4, Vertex (NASDAQ:VRTX) reported non-GAAP EPS